Skip to main content
Vcanbio Cell & Gene Engineering Corp., Ltd logo

Vcanbio Cell & Gene Engineering Corp., Ltd — Investor Relations & Filings

Ticker · 600645 ISIN · CNE000000545 LEI · 300300FLWFDJPQYVAZ24 Shanghai Stock Exchange Professional, scientific and technical activities
Open in API
Filings indexed 2,580 across all filing types
Latest filing 2017-09-11 Board/Management Inform…
Country CN China
Listing Shanghai Stock Exchange 600645

About Vcanbio Cell & Gene Engineering Corp., Ltd

https://www.vcanbio.com/

Vcanbio Cell & Gene Engineering Corp., Ltd. specializes in the fields of cell therapy, gene technology, and precision medicine. The company operates a comprehensive business model centered on the storage of hematopoietic and mesenchymal stem cells, providing long-term bio-banking services for cord blood and other biological tissues. Its technical portfolio includes advanced genetic testing services, such as prenatal screening and oncology diagnostics, alongside the development of cell-based therapeutic products. Vcanbio maintains a network of specialized laboratories and storage facilities to support clinical research and personalized healthcare applications. The organization focuses on translating biotechnological advancements into clinical solutions, emphasizing quality control in cell processing and genomic analysis to serve the evolving needs of the regenerative medicine and diagnostic sectors.

Recent filings

Filing Released Lang Actions
第九届董事会第四次会议决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement of resolutions passed at the fourth meeting of the ninth board of directors of the company. It details voting results on various proposals including guarantees, financing leasing, stock repurchase plans, capital changes, and convening a shareholders meeting. The content focuses on board decisions and approvals rather than financial results or reports. It also references other announcements for detailed information. The document length is 2326 characters, which is relatively short and consistent with a board meeting resolution announcement. Therefore, this fits the category of Board/Management Information (MANG).
2017-09-11 Chinese
北京国枫律师事务所关于中源协和细胞基因工程股份有限公司限制性股票激励计划之限制性股票回购注销相关事宜的法律意见书
Regulatory Filings
2017-09-11 Chinese
独立董事关于回购注销限制性股票事项的独立意见
Transaction in Own Shares Classification · 95% confidence The document is an independent director's opinion on the repurchase and cancellation of restricted shares, referencing relevant laws and company regulations. It discusses the conditions of a stock incentive plan and the decision to repurchase and cancel shares due to unmet performance targets. The document is a formal opinion related to a share repurchase transaction, not a full financial report or earnings release. It is not a general announcement or a report publication notice but a specific statement on a transaction involving the company's own shares. Therefore, it fits best under the category of Transaction in Own Shares (POS). The document length is short (1014 characters), but it contains substantive content about the transaction, not just an announcement or certification.
2017-09-11 Chinese
关于回购注销未达到解锁条件的限制性股票减少注册资本的债权人公告
Share Issue/Capital Change Classification · 95% confidence The document is an announcement from Zhongyuan Xiehe Cell Gene Engineering Co., Ltd. regarding the repurchase and cancellation of restricted shares that have not met unlocking conditions, resulting in a reduction of registered capital. It includes details about the repurchase plan, the number of shares involved, the reduction in registered capital, and a creditor notification period for debt claims. The document is a formal public notice related to share repurchase and capital reduction, not a financial report or earnings release. It does not contain financial statements or detailed financial data but rather informs creditors about their rights during the capital reduction process. This fits the category of a Share Issue/Capital Change announcement, as it concerns changes in the company's capital structure due to share repurchase and cancellation.
2017-09-11 Chinese
2017年度预计担保额度的公告
Capital/Financing Update Classification · 95% confidence The document is an official announcement from a listed company (证券代码：600645) regarding the expected guarantee amount for the year 2017. It details the guarantee limits the company and its subsidiaries plan to provide to each other, including financial data of the subsidiaries, internal decision procedures, and board opinions on the guarantees. The document references regulatory notices from the China Securities Regulatory Commission about external guarantees. It is a disclosure about financing guarantees and risk management rather than a financial report or earnings release. The document length is 4378 characters, which is relatively short and focused on a specific financing-related announcement. Therefore, it fits best under the category of Capital/Financing Update (CAP), as it concerns the company's financing activities and guarantee commitments rather than a full financial report or other categories.
2017-09-11 Chinese
关于公司及子公司与北京市文化科技融资租赁股份有限公司开展融资租赁业务的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement by the company 中源协和细胞基因工程股份有限公司 regarding a financing lease transaction involving the company and its subsidiary with a third-party leasing company. It details the financing lease business, the parties involved, the asset used as collateral (patent rights), the financing amount, and the purpose and impact of the transaction. The document is relatively short (1349 characters) and focuses on a financing activity rather than presenting financial results or detailed financial statements. It is not an earnings release or annual/interim report. The content fits the category of a Capital/Financing Update, as it provides information on a financing transaction and capital structure change. Therefore, the appropriate classification is CAP (Capital/Financing Update).
2017-09-11 Chinese

Browse filings by year

27 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.